Laura Conklin1, James J Sejvar2, Stephanie Kieszak1, Raquel Sabogal1, Carlos Sanchez1, Dana Flanders1, Felicia Tulloch3, Gerardo Victoria3, Giselle Rodriguez4, Nestor Sosa5, Michael A McGeehin1, Joshua G Schier6. 1. Division of Environmental Hazards and Health Effects, National Centers for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia. 2. Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia. 3. Hospital Santo Tomás, Panama City, Panama. 4. Caja de Seguro Social, Panama City, Panama. 5. The Gorgas Memorial Institute, Panama City, Panama. 6. Division of Environmental Hazards and Health Effects, National Centers for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia6Emory University School of Medicine, Department of Emergency Medicine, Atlanta, Georgia.
Abstract
IMPORTANCE: At least 13 medication-associated diethylene glycol (DEG) mass poisonings have occurred since 1937. To our knowledge, this is the first longitudinal study characterizing long-term health outcomes among survivors beyond the acute poisoning period. OBJECTIVE: To characterize renal and neurologic outcomes among survivors of a 2006 DEG mass-poisoning event in Panama for 2 years after exposure. DESIGN, SETTING, AND PARTICIPANTS: This prospective longitudinal study used descriptive statistics and mixed-effects repeated-measures analysis to evaluate DEG-poisoned survivors at 4 consecutive 6-month intervals (0, 6, 12, and 18 months). Case patients included outbreak survivors with a history of (1) ingestion of DEG-contaminated medication, (2) hospitalization for DEG poisoning, and (3) an unexplained serum creatinine level of 1.5 mg/dL or higher (to convert to micromoles per liter, multiply by 88.4) during acute illness or unexplained exacerbation of preexisting end-stage renal disease. MAIN OUTCOMES AND MEASURES: Demographics, mortality, dialysis dependence, renal function, neurologic signs and symptoms, and nerve conduction studies. RESULTS: Of the 32 patients enrolled, 5 (15.6%) died and 1 was lost to follow-up, leaving 26 patients at 18 months. Three (9.4%) missed 1 or more evaluations. The median age was 62 years (range, 15-88 years), and 59.4% were female. Three (9.4%) patients had preexisting renal failure. Enrollment evaluations occurred at a median of 108 days (range, 65-154 days) after acute illness. The median serum creatinine level for the 22 patients who were not dialysis dependent at time 0 was 5.9 mg/dL (range, 1.8-17.1 mg/dL) during acute illness and 1.8 mg/dL (range, 0.9-5.9 mg/dL) at time 0. Among non-dialysis-dependent patients, there were no significant differences in the log of serum creatinine or estimated glomerular filtration rate over time. The number of patients with subjective generalized weakness declined significantly over time (P < .001). A similar finding was observed for any sensory loss (P = .05). The most common deficits at enrollment were bilateral lower extremity numbness in 13 patients (40.6%) and peripheral facial nerve motor deficits in 7 (21.9%). All patients with neurologic deficits at enrollment demonstrated improvement in motor function over time. Among 28 patients (90.3%) with abnormal nerve conduction study findings at enrollment, 10 (35.7%) had motor axonal involvement, the most common primary abnormality. CONCLUSIONS AND RELEVANCE: Neurologic findings of survivors tended to improve over time. Renal function generally improved among non-dialysis-dependent patients between acute illness and the first evaluation with little variability thereafter. No evidence of delayed-onset neurologic or renal disease was observed.
IMPORTANCE: At least 13 medication-associated diethylene glycol (DEG) mass poisonings have occurred since 1937. To our knowledge, this is the first longitudinal study characterizing long-term health outcomes among survivors beyond the acute poisoning period. OBJECTIVE: To characterize renal and neurologic outcomes among survivors of a 2006 DEG mass-poisoning event in Panama for 2 years after exposure. DESIGN, SETTING, AND PARTICIPANTS: This prospective longitudinal study used descriptive statistics and mixed-effects repeated-measures analysis to evaluate DEG-poisoned survivors at 4 consecutive 6-month intervals (0, 6, 12, and 18 months). Case patients included outbreak survivors with a history of (1) ingestion of DEG-contaminated medication, (2) hospitalization for DEGpoisoning, and (3) an unexplained serum creatinine level of 1.5 mg/dL or higher (to convert to micromoles per liter, multiply by 88.4) during acute illness or unexplained exacerbation of preexisting end-stage renal disease. MAIN OUTCOMES AND MEASURES: Demographics, mortality, dialysis dependence, renal function, neurologic signs and symptoms, and nerve conduction studies. RESULTS: Of the 32 patients enrolled, 5 (15.6%) died and 1 was lost to follow-up, leaving 26 patients at 18 months. Three (9.4%) missed 1 or more evaluations. The median age was 62 years (range, 15-88 years), and 59.4% were female. Three (9.4%) patients had preexisting renal failure. Enrollment evaluations occurred at a median of 108 days (range, 65-154 days) after acute illness. The median serum creatinine level for the 22 patients who were not dialysis dependent at time 0 was 5.9 mg/dL (range, 1.8-17.1 mg/dL) during acute illness and 1.8 mg/dL (range, 0.9-5.9 mg/dL) at time 0. Among non-dialysis-dependent patients, there were no significant differences in the log of serum creatinine or estimated glomerular filtration rate over time. The number of patients with subjective generalized weakness declined significantly over time (P < .001). A similar finding was observed for any sensory loss (P = .05). The most common deficits at enrollment were bilateral lower extremity numbness in 13 patients (40.6%) and peripheral facial nerve motor deficits in 7 (21.9%). All patients with neurologic deficits at enrollment demonstrated improvement in motor function over time. Among 28 patients (90.3%) with abnormal nerve conduction study findings at enrollment, 10 (35.7%) had motor axonal involvement, the most common primary abnormality. CONCLUSIONS AND RELEVANCE: Neurologic findings of survivors tended to improve over time. Renal function generally improved among non-dialysis-dependent patients between acute illness and the first evaluation with little variability thereafter. No evidence of delayed-onset neurologic or renal disease was observed.
Authors: Lauren M Besenhofer; Marie C McLaren; Brian Latimer; Michael Bartels; Mark J Filary; Adam W Perala; Kenneth E McMartin Journal: Toxicol Sci Date: 2011-07-29 Impact factor: 4.849
Authors: Sam Alfred; Patrick Coleman; David Harris; Tim Wigmore; Edward Stachowski; Andis Graudins Journal: Clin Toxicol (Phila) Date: 2005 Impact factor: 4.467
Authors: Joshua G Schier; Carol S Rubin; Dorothy Miller; Dana Barr; Michael A McGeehin Journal: J Public Health Policy Date: 2009-07 Impact factor: 2.222
Authors: E Danielle Rentz; Lauren Lewis; Oscar J Mujica; Dana B Barr; Joshua G Schier; Gayanga Weerasekera; Peter Kuklenyik; Michael McGeehin; John Osterloh; Jacob Wamsley; Washington Lum; Camilo Alleyne; Nestor Sosa; Jorge Motta; Carol Rubin Journal: Bull World Health Organ Date: 2008-10 Impact factor: 9.408
Authors: Rupesh Raina; Manpreet K Grewal; Martha Blackford; Jordan M Symons; Michael J G Somers; Christoph Licht; Rajit K Basu; Sidharth Kumar Sethi; Deepa Chand; Gaurav Kapur; Mignon McCulloch; Arvind Bagga; Vinod Krishnappa; Hui-Kim Yap; Marcelo de Sousa Tavares; Timothy E Bunchman; Michelle Bestic; Bradley A Warady; Maria Díaz-González de Ferris Journal: Pediatr Nephrol Date: 2019-08-24 Impact factor: 3.714
Authors: Miriam E Mossoba; Sanah Vohra; Howard Toomer; Shelia Pugh-Bishop; Zachary Keltner; Vanessa Topping; Thomas Black; Nicholas Olejnik; Ana Depina; Kathleen Belgrave; Jessica Sprando; Joyce Njorge; Thomas J Flynn; Paddy L Wiesenfeld; Robert L Sprando Journal: Toxicol Rep Date: 2017-06-23